Stay updated on Tesetaxel+PD-(L)1 Inhibitors in Triple-Negative MBC Clinical Trial
Sign up to get notified when there's something new on the Tesetaxel+PD-(L)1 Inhibitors in Triple-Negative MBC Clinical Trial page.

Latest updates to the Tesetaxel+PD-(L)1 Inhibitors in Triple-Negative MBC Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check46 days agoChange DetectedThe page has undergone significant updates, including the removal of detailed descriptions of the CONTESSA TRIO study and the addition of new drug names and a revision number. The focus has shifted towards a more concise presentation of the study's purpose and drug information.SummaryDifference39%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check60 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check96 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Tesetaxel+PD-(L)1 Inhibitors in Triple-Negative MBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tesetaxel+PD-(L)1 Inhibitors in Triple-Negative MBC Clinical Trial page.